PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report
Journal of Cystic Fibrosis · 2025-11 · 24 (6) · 1058-1066
DOI: 10.1016/j.jcf.2025.07.015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2025-11. Verfasst von Sylvia Szentpetery und 21 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of South Carolina, Department of Pediatrics, Charleston, SC, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Fetal Therapies. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Data from cystic fibrosis (CF) animal models and case studies suggests that in utero administration of CF transmembrane conductance regulator (CFTR) modulators (variant specific therapies, VST) can rescue CFTR-related pathophysiology in the fetus. Use of VST during pregnancy to prevent disease in infants has not been systematically studied. Through stakeholder engagement, we sought to determine if formal research evaluation is warranted. METHODS: We surveyed CF care center directors to assess their awareness of the potential off-label use of VST for in utero treatment of a fetus with CF. We then conducted a one-day, international multidisciplinary workshop to review available pre-clinical and clinical data, embryology principles and federal drug regulation considerations, identify knowledge gaps, and consider future clinical study designs. RESULTS: Sixty-two unique individuals responded to the survey; 92% were aware of use of VST to treat pregnant females who are CF carriers for the prevention of CF complications in the fetus. Expert workshop presentations suggested that use of VST in pregnant females carrying a fetus with CF to mitigate complications of CF is relatively safe and effective in animal models and human case series to date. Further research is needed to understand the optimal timing of VST initiation during pregnancy to improve clinical outcomes, to understand VST pharmacokinetics, and optimize dosing of VST during pregnancy and lactation, and to evaluate the long-term infant safety among those exposed to VST in utero. CONCLUSIONS: Based on available data and knowledge gaps, stakeholders agreed that formal evaluation of in utero and early life VST therapy in a prospective trial is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical University of South Carolina, Department of Pediatrics, Charleston, SC, USA.
- Cystic Fibrosis Foundation, Bethesda, MD, USA.
- Department of Obstetrics & Gynecology, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Anatomy and Cell Biology, University of Iowa, Carver College of Medicine, Iowa City, IA, USA.
- Multidisciplinary Cystic Fibrosis Unit. Department of Paediatrics. Hospital Universitario 12 de Octubre, Madrid, Spain.
- Center for Excellence in Pulmonary Biology, Stanford University, Palo Alto, CA USA.
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- Indiana University
- National Health and Medical Research Council
- National Heart, Lung, and Blood Institute
- National Jewish Health
Zitieren
APA
Szentpetery, S., Riva, D., Blumenfeld, Y. J., Engelhardt, J. F., Luna-Paredes, C., Milla, C., Schneider-Futschik, E. K., Sheffield, J. S., Darrah, R., Davies, J. C., Flume, P. A., Foil, K. E., Fortner, C. N., Guimbellot, J. S., Lyerly, A. D., Mayer-Hamblett, N., Ren, C. L., Spano, J., Tillman, E. M., …, & Taylor-Cousar, J. L. (2025). PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report. Journal of Cystic Fibrosis, 24(6), 1058-1066. https://doi.org/10.1016/j.jcf.2025.07.015
Vancouver
Szentpetery S, Riva D, Blumenfeld YJ, Engelhardt JF, Luna-Paredes C, Milla C, et al. PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report. Journal of Cystic Fibrosis. 2025;24(6):1058-1066. doi:10.1016/j.jcf.2025.07.015
BibTeX
@article{Szentpetery2025,
author = {Szentpetery, Sylvia and Riva, Dara and Blumenfeld, Yair J and Engelhardt, John F and Luna-Paredes, Carmen and Milla, Carlos and Schneider-Futschik, Elena K and Sheffield, Jeanne S and Darrah, Rebecca and Davies, Jane C and Flume, Patrick A and Foil, Kimberly E and Fortner, Christopher N and Guimbellot, Jennifer S and Lyerly, Anne D and Mayer-Hamblett, Nicole and Ren, Clement L and Spano, Jacquelyn and Tillman, Emma M and Trimble, Aaron and Wilfond, Benjamin S and Taylor-Cousar, Jennifer L},
title = {PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {6},
pages = {1058--1066},
doi = {10.1016/j.jcf.2025.07.015}
}
EUVIMED